Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by
The approval by the
(C) 2022 Electronic News Publishing, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,117 GBX | +0.77% | +7.54% | +14.32% |
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by
The approval by the
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+14.32% | 234B | |
+26.47% | 664B | |
+30.25% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+4.95% | 199B | |
-10.02% | 196B | |
-4.04% | 148B | |
-10.94% | 145B |